Difference between revisions of "Lipefilgrastim (Lonquex)"
Jump to navigation
Jump to search
m (Jwarner moved page Lipefilgrastim (XM22) to Lipefilgrastim (Lonquex): EMA approval) |
m |
||
Line 2: | Line 2: | ||
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation." | From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation." | ||
+ | ==History of changes in EMA indication== | ||
+ | *7/25/2013: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' XM22 | *'''Code name:''' XM22 | ||
+ | *'''Brand name:''' Lonquex | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 9: | Line 12: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
[[Category:Granulocyte colony-stimulating factors]] | [[Category:Granulocyte colony-stimulating factors]] | ||
− | [[Category: | + | [[Category:EMA approved in 2013]] |
[[Category:Stub]] | [[Category:Stub]] |
Revision as of 12:32, 31 December 2022
Mechanism of action
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
History of changes in EMA indication
- 7/25/2013: Initial authorization
Also known as
- Code name: XM22
- Brand name: Lonquex